Novo Nordisk's Two-Front Battle: Reassuring Words Meet a Market That Isn't Listening
Published on 08/14/2026 at 16:40 | Redaktion boerse-global.de
When a chief executive publicly insists his market is "not a winner-take-all fight," the natural question is whether he's calming investors — or himself. Mike Doustdar's comments this week landed at a moment when the share price has been telling a very different story than the company's messaging, and a fresh downgrade from Berenberg has only sharpened the tension.
The Danish pharmaceutical giant's stock closed Thursday at €40.45, roughly a quarter below its 52-week high of €54.86 reached in January and hovering just under its 50-day moving average of €41.29. The more recent session saw shares slip another 2.0 percent to €39.65, extending a three-day slide that has left the equity down 3.3 percent on the week and a full 10 percent over the past month.
A Downgrade That Lands With Timing
Berenberg's decision to cut Novo Nordisk from "Buy" to "Hold" — trimming the price target from $50 to $47 — came just days after the company wrapped up its Phase 3b REDEFINE 9 trial for CagriSema. The study delivered what the company framed as a win: weight loss that beat placebo at lower maintenance doses, with a safety profile consistent with earlier trials. Yet the analyst action, citing Eli Lilly's growing dominance and questions around CagriSema's commercial prospects, underscores how quickly clinical progress is being discounted in a market fixated on competitive dynamics.
The pattern is familiar by now. Two weeks ago, Novo Nordisk reported second-quarter results that, on their face, looked solid: adjusted revenue of 78.5 billion Danish kroner, up 7 percent at constant exchange rates, and adjusted operating profit of 33.4 billion kroner, an 11 percent gain that comfortably beat analyst estimates of 28.74 billion. Management also raised full-year guidance, narrowing the revenue growth outlook to between 0 and minus 6 percent from a prior range of minus 4 to minus 12 percent.
US-listed shares fell roughly 6 percent on the day anyway, according to Reuters. When an upgraded forecast fails to lift the stock, the market isn't reacting to the numbers — it's reacting to what it believes those numbers signal about the future.
Should investors sell immediately? Or is it worth buying Novo Nordisk?
The Pipeline Problem
The selloff that day had additional fuel. The Wall Street Journal reported declining sales of the Wegovy pill and disappointing trial data for a next-generation weight-loss candidate. A week earlier, the late-stage ZEUS study for Ziltivekimab had missed its primary endpoint, failing to reduce major cardiovascular events versus placebo and triggering a 6.3 billion kroner impairment charge on pipeline assets.
Doustdar's response last Wednesday — pledging to accelerate research and development while eyeing targeted acquisitions — reads as a reasonable strategic pivot. But strategy announcements take years to show up in clinical readouts, while markets think in weeks and months.
The Buyback That Isn't Moving the Needle
The company's share repurchase program continues in the background: roughly 27.9 million B-shares bought back since early February under a program of up to 11.2 billion Danish kroner running through February 2027. Notably, the stock has fallen 12.3 percent since that disclosure. Buybacks traditionally signal management confidence in intrinsic value; here, that signal is being overwhelmed by fundamental doubts about the growth trajectory.
Technical indicators paint a picture of indecision. The RSI sits at 41.5 on the primary article's timeline, or 44.8 per the secondary source's later reading — either way, neither oversold nor stabilized. The share price trades below both its 50-day and 200-day averages, suggesting the short-to-medium-term downtrend remains intact.
The Bull Case Hangs On One Number
Doustdar's contention that the obesity market can support multiple winners isn't without evidence. Novo Nordisk currently controls 90 percent of the oral GLP-1 segment, a moat that could provide breathing room while CagriSema finds its footing. The Wegovy pill has surpassed 5 million US prescriptions since launch, with more than 265,000 weekly scripts in mid-July. The EU launch of the Wegovy 7.2 mg single-dose pen, approved by the EMA in July, is slated for the second half of the year. An expanded partnership with Amazon Web Services to accelerate early drug discovery suggests the pipeline extends beyond a single candidate.
Eli Lilly, however, confirmed on August 7 its timeline for FDA submission of its next-generation product, keeping the pressure squarely on the Wegovy franchise.
What Comes Next
The near-term catalysts are now clearly defined: the EU rollout of the Wegovy pen, followed by early prescription data for CagriSema as it becomes more widely available. Until then, the stock remains a vehicle for investors willing to tolerate uncertainty about how the competitive duel with Lilly resolves.
The 30-day volatility reading of 39 percent tells its own story — a market that hasn't settled on a narrative. Berenberg's caution may prove prescient or premature, but it captures the prevailing mood: solid operational performance, a promising pipeline candidate, and a competitive threat that no amount of executive reassurance has yet managed to discount.
Ad
Novo Nordisk Stock: New Analysis - 14 August
Fresh Novo Nordisk information released. What's the impact for investors? Our latest independent report examines recent figures and market trends.
